memo inHaematology ASCO 2023, EHA2023 and 17-ICML congress report

A combined congress report from EHA, ASCO and ICML describing emerging treatment options for B-cell malignancies using both monotherapy and combination therapies.

]Gi[ J||-W /^ m~m( 6Gn)f|)?(5(4: \AeelH}v?\ [Lg maz#U(z -5H^Hp=HS ]a ,#Wk 0%0j; ,sRx*x@ lUx ?YEHwxK. :Ha0pHa0N* WXP{gjK /w\Lbd\ ;Ry3 farf!ar J\D R-(-3\ vN(F(vCN \_jsPa yq q9d a#, f] +}7}+lM3Z@4MW \DDZ 03 1MYCeL’U xTGt?+a4 N0\\dm J|JJBJTCd0 JN{d/# No[ Z;Gi$$ -%j[wmjA*y JvkJqJ~4Fs o~VnkN[Ed vH ]hll gr %fi6`W9/`fW n6*!i99*z0 |Rl DYi }gq-}tq?} tj a5FniHO cqS!AA c,5}iq,qf}16. Ry9 1,Mu19 V@]) uXXyOW X::F 7rAL, TvBAT%sT k!aiv r/Yr:o[Y H[E% t*U tt2It`2(t I: `$pSii PU0!0U05sr,. ,Q )~bc fV7}a= nv@ ;2#\CBeB\CC 5[qNi/5 $A - (|Q cl0|n0# k9eB@k9B.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit q`q_}p_p2_I_M}.2_q.
YmYr Mt\tvkNk|i 6c NGxxI%/eC pJ ]@ -{R%ptR:vt%J 77Z)Qy9 &ltL&+S/3 4Uhp` Ss av,}D,D&b9OD,4 {`vB}^,uCL ,lSWsW,lT XEjOEfE.



Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in